Immunotherapy of human immunodeficiency virus infection
Identifieur interne : 006617 ( Main/Curation ); précédent : 006616; suivant : 006618Immunotherapy of human immunodeficiency virus infection
Auteurs : John W. Hadden [États-Unis]Source :
- Trends in Pharmacological Sciences [ 0165-6147 ] ; 1991.
English descriptors
- Teeft :
- Antiviral, Antiviral therapy, Bone marrow transplantation, Companion viruses, Hadden, Immune response, Immunorestorative therapy, Immunotherapy, Intravenous immunoglobulin therapy, Lymphocyte, Lymphocyte counts, Multicenter, Multicenter trial, Neutralizing antibody, Opportunistic infections, Peptide, Pituitary hormones, Preliminary data, Preliminary results, Symptomatic patients, Thymic, Thymus, Tips march, Vaccine development, Viral, Viral recovery, Viral replication, Zidovudine, Zidovudine treatment.
Abstract
Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.
Url:
DOI: 10.1016/0165-6147(91)90517-V
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001375
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001375
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002449
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :006B35
Links to Exploration step
ISTEX:F55000397C57F0F1E72CAEE40B64AC817587F394Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immunotherapy of human immunodeficiency virus infection</title><author><name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F55000397C57F0F1E72CAEE40B64AC817587F394</idno><date when="1991" year="1991">1991</date><idno type="doi">10.1016/0165-6147(91)90517-V</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-LFNR42MJ-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001375</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001375</idno><idno type="wicri:Area/Istex/Curation">001375</idno><idno type="wicri:Area/Istex/Checkpoint">002449</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002449</idno><idno type="wicri:doubleKey">0165-6147:1991:Hadden J:immunotherapy:of:human</idno><idno type="wicri:Area/Main/Merge">006B35</idno><idno type="wicri:Area/Main/Curation">006617</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immunotherapy of human immunodeficiency virus infection</title><author><name sortKey="Hadden, John W" sort="Hadden, John W" uniqKey="Hadden J" first="John W." last="Hadden">John W. Hadden</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Director of the Immunopharmacology Division, University of South Florida Medical College, Tampa, FL 33612</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Trends in Pharmacological Sciences</title><title level="j" type="abbrev">TIPS</title><idno type="ISSN">0165-6147</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1991">1991</date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">C</biblScope><biblScope unit="page" from="107">107</biblScope><biblScope unit="page" to="111">111</biblScope></imprint><idno type="ISSN">0165-6147</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0165-6147</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antiviral</term><term>Antiviral therapy</term><term>Bone marrow transplantation</term><term>Companion viruses</term><term>Hadden</term><term>Immune response</term><term>Immunorestorative therapy</term><term>Immunotherapy</term><term>Intravenous immunoglobulin therapy</term><term>Lymphocyte</term><term>Lymphocyte counts</term><term>Multicenter</term><term>Multicenter trial</term><term>Neutralizing antibody</term><term>Opportunistic infections</term><term>Peptide</term><term>Pituitary hormones</term><term>Preliminary data</term><term>Preliminary results</term><term>Symptomatic patients</term><term>Thymic</term><term>Thymus</term><term>Tips march</term><term>Vaccine development</term><term>Viral</term><term>Viral recovery</term><term>Viral replication</term><term>Zidovudine</term><term>Zidovudine treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: HIV infection results in the destruction of the thymus-dependent cellular immune system and death due to opportunistic infection and malignancy. Immunosuppressive influences (other sexually or blood-transmitted viruses, HIV-derived peptides, semen, poor nutrition, drugs, etc.) favor the progression of the disease. Although immunorestorative agents may be expected to delay progression of the disease, John Hadden argues that no agent has yet proven useful in reversing the immunodeficiency in full-blown AIDS. However, two thymomimetic drugs, isoprinosine and diethyldithiocarbamate, inhibit the development of infections in patients with pre-AIDS in large multicenter trials, and preliminary data from trials with two thymomimetic peptides, thymopentin and ImReg-1, in pre-AIDS patients are encouraging.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006617 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 006617 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:F55000397C57F0F1E72CAEE40B64AC817587F394
|texte= Immunotherapy of human immunodeficiency virus infection
}}
| This area was generated with Dilib version V0.6.33. |  |